

Cover Story
By Matthew Bin Han Ong
After an examination of the causes of an avalanche of grant applications directed at NCI, institute officials found that new applications largely come from principal investigators who are switching their research focus to cancer. No other NIH institute or center faces such pressure.
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for December 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Preparing to take care of each other in ways we never imagined
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”